search
Back to results

DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral Fusion

Primary Purpose

Degenerative Lumbar Spinal Stenosis

Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Single-Level Posterior Decompression
DIAM Spinal Stabilization
DIAM Spinal Stabilization
Fusion
Sponsored by
Medtronic Spinal and Biologics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Degenerative Lumbar Spinal Stenosis

Eligibility Criteria

35 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Has a symptom complex consisting of back, buttock, or groin pain (excluding symptomatic coxarthrosis) with leg pain typical of intermittent neurogenic claudication, which is defined as leg(usually calf) discomfort, pain, numbness, paresthesias, weakness, or fatigue aggravated by standing or walking and is only relieved with resting in flexed lumbar spine position
  • Leg pain score ≥ 8 and back pain score ≥ 6 based on the Preop Back/ Leg Pain CRF.

Leg pain score must be ≥ back pain score

  • Narrowing of the lumbar spinal canal and/or intervertebral foramen at L2-L3, L3-L4, L4-L5 as indicated by MRI, with other MRI findings typical of spinal stenosis, such as trefoil canal shape; hypertrophy, thickening, buckling, or infolding of the ligamentum flavum; hypertrophied facet joints or facet joint capsule; annular bulging; or lateral (subarticular) stenosis.
  • Must sit for at least 30 min without severe pain
  • Must walk at least 100 ft unassisted
  • 35 yrs of age, inclusive
  • Preoperative Oswestry score ≥ 40
  • Child-bearing potential, pt is not pregnant or nursing and agrees not to become pregnant during study period
  • Treated non-operatively for a pd of at least 6 mos
  • Willing and able to comply with study plan and able to understand and sign Pt ICF

Exclusion Criteria:

  • Disease state which requires destabilizing decompression
  • Axial back pain with no pain in leg, buttock, or groin
  • Baseline strength grade of 0 (total paralysis), 1 (palpable or visible contraction), or 2 (active movement, gravity,eliminated) in any lower extremity motor group as noted on Neuro Status CRF
  • Segmental kyphosis >0° at indicated level
  • Cauda equina syndrome
  • Compression of nerve roots that causes neurogenic bowel, bladder dysfunction
  • Prior surgical procedure at involved or adjacent levels
  • Diagnosed with significant peripheral neuropathy
  • Significant vascular disease causing vascular claudication
  • Requires tx of spinal stenosis at more than 1 lumbar level
  • Significant lumbar instability, defined as > 3mm translation on flexion/extension radiographs
  • Has > 3mm fixed spondylolisthesis at affected level
  • BMI ≥ 40
  • Sustained vertebral or hip fracture within last year
  • Has the following (if "Yes" to any risk below, a lumbar spine DEXA Scan is required for eligibility)

    1. Previous diagnosis of osteoporosis, osteopenia, or osteomalacia
    2. Postmenopausal Non-Black female over age of 60 who weighs ≤ 140 lbs
    3. Postmenopausal female who has sustained a non traumatic hip, spine or wrist fracture
    4. Male over age of 60 who has sustained non-traumatic hip or spine fracture
  • If level of DEXA T-score is -1.0 or lower pt is excluded from study
  • Lumbar scoliosis with Cobb angle of > 15°
  • Documented allergy to silicone, polyethylene, titanium or latex
  • Overt or active bacterial infection, local, systemic, and/or potential for bacteremia
  • Alcohol and/or drug abuser
  • Received tx with investigational therapy (device and/or pharmaceutical) within 30 days prior to entering study or such tx is planned during the 24 mos following enrollment in study
  • Suppressed immune system or has taken steroids at any dose daily for more than 1 mon within the last yr
  • Presence of active malignancy or prior history of malignancy except for basal cell carcinoma of the skin
  • History of any endocrine or metabolic disorder known to affect osteogenesis
  • Chronic or acute renal and/or hepatic failure or prior history of renal and/or hepatic parenchymal disease
  • History of autoimmune disease
  • Disease which precludes accurate clinical evaluation of safety and effectiveness of txs in this study
  • Congenital or iatrogenic posterior element insufficiency
  • Moderate to advance spondylosis or pts who demonstrate advanced degenerative changes. Such advanced degenerative changes are characterized by 1 or combination of the following a Bridging osteophytes; b Reduction or absence of motion; c Collapse of the intervertebral disc space of > 50% of its normal ht
  • Mentally incompetent
  • Waddell Signs of Inorganic Behavior score of ≥ 3
  • Prisoner

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Experimental

Active Comparator

Arm Label

DIAM Group1

Single-Level Posterior Decompression

DIAM Group2

Posterolateral Interbody Fusion

Arm Description

Outcomes

Primary Outcome Measures

Rate of Overall Success
Rate of overall success is reported as the percentage of partipants who met all of the following criteria: Pain/disability (ODI) success:(Success of ODI is defined as pain/disability improvement according to the definition: Pre-treatment Score - Post-treatment Score ≥ 15); Neurological success (Neurological success is defined as maintenance or improvement in sections of motor, sensory, reflex, and straight leg raise for the time period evaluated); No serious adverse event classified as "surgical treatment associated"; No additional surgical procedure classified as "failure."

Secondary Outcome Measures

Oswestry Disability Index (ODI) Score
The self-administered Oswestry Disability Index (ODI) Questionnaire was used to assess patient pain and ability to function. The ODI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).
Success Rate of Oswestry Diability Index Scores
Success rate of Oswestry Diability Index Scores is reported as the percentage of participants who met: Pre-treatment Score - Post-treatment Score ≥ 15.
Success Rate of Neurological Status
Success rate of neurological status is reported as the percentage of participants who met neurological success defined as maintenance or improvement in all sections (motor, sensory, reflex, and straight leg raising) for the time period evaluated. In order for a section to be considered a success, each element in the section must remain the same or improve from the time of the preoperative evaluation to the time period evaluated.
Back Pain
Numerical rating scales are used to evaluate back pain intensity and frequency. Patients will rate their pain intensity on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be." Similarly, patients will record their back pain frequency on a scale from 0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time." A patient's total pain score will be the sum of pain intensity and frequency scores (0 min, 20 max).
Back Pain Success Rate
Back pain success rate is reported as the percentage of participants whose back pain improvement met: (Pre Score - Post Score)/ Pre Score > 20%.
Leg Pain
Numerical rating scales are used to evaluate leg intensity and frequency. Patients will rate their pain intensity on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be." Similarly, patients will record their back pain frequency on a scale from 0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time." A patient's total pain score will be the sum of pain intensity and frequency scores (0 min, 20 max).
Leg Pain Success Rate
Leg pain success rate is reported as the percentage of participants whose leg pain improvement met: (Pre Score - Post Score)/ Pre Score > 20%.
General Health Status (SF-36)
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results are summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for PCS and MCS is between 0 and 100, with higher scores denoting better quality of life.
Success Rate of SF-36 Health Survey
Success rate of SF-36 Health Survey include two components: the success rate of a physical component summary (PCS) and the success rate of a mental component summary (MCS). The success rates of SF-36 PCS and MCS for DIAM Device vs. Single-Level Posterior Decompression were defined as: (Post Score - Pre Score) / Pre Score>= 20%. The success rates of SF-36 PCS and MCS for DIAM vs. Posterolateral Interbody Fusion were defined as: Post Score - Pre Score >= 0.
Operative Time
Blood Loss
Hospital Stay

Full Information

First Posted
February 21, 2008
Last Updated
December 10, 2020
Sponsor
Medtronic Spinal and Biologics
search

1. Study Identification

Unique Protocol Identification Number
NCT00627497
Brief Title
DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral Fusion
Official Title
A Prospective, Randomized, Controlled Pivotal Clinical Investigation of DIAM™ Spinal Stabilization System in Patients With Degenerative Lumbar Spinal Stenosis.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Terminated
Why Stopped
slow patient recruitment
Study Start Date
February 2008 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Spinal and Biologics

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this clinical trial is to evaluate the safety and effectiveness of the DIAM Spinal Stabilization System as a method of treating patients with symptoms of degenerative lumbar spinal stenosis at a single level from L2 to L5.
Detailed Description
This pivotal clinical trial is being conducted to evaluate the DIAM Spinal Stabilization System for the treatment of single-level degenerative lumbar spinal stenosis from L2 to L5. The implant under investigation in this clinical trial is the DIAM Spinal Stabilization System. And following a decompression procedure, the device will be implanted using a posterior surgical approach. Patients in the control group will receive a lumbar decompression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Degenerative Lumbar Spinal Stenosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
DIAM Group1
Arm Type
Experimental
Arm Title
Single-Level Posterior Decompression
Arm Type
Active Comparator
Arm Title
DIAM Group2
Arm Type
Experimental
Arm Title
Posterolateral Interbody Fusion
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Single-Level Posterior Decompression
Intervention Description
The single level posterior decompression is a posterior surgical procedure.
Intervention Type
Device
Intervention Name(s)
DIAM Spinal Stabilization
Intervention Description
The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
Intervention Type
Device
Intervention Name(s)
DIAM Spinal Stabilization
Intervention Description
The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
Intervention Type
Device
Intervention Name(s)
Fusion
Intervention Description
Posterolateral Interbody Fusion
Primary Outcome Measure Information:
Title
Rate of Overall Success
Description
Rate of overall success is reported as the percentage of partipants who met all of the following criteria: Pain/disability (ODI) success:(Success of ODI is defined as pain/disability improvement according to the definition: Pre-treatment Score - Post-treatment Score ≥ 15); Neurological success (Neurological success is defined as maintenance or improvement in sections of motor, sensory, reflex, and straight leg raise for the time period evaluated); No serious adverse event classified as "surgical treatment associated"; No additional surgical procedure classified as "failure."
Time Frame
24 months after operation
Secondary Outcome Measure Information:
Title
Oswestry Disability Index (ODI) Score
Description
The self-administered Oswestry Disability Index (ODI) Questionnaire was used to assess patient pain and ability to function. The ODI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).
Time Frame
24 month after operation
Title
Success Rate of Oswestry Diability Index Scores
Description
Success rate of Oswestry Diability Index Scores is reported as the percentage of participants who met: Pre-treatment Score - Post-treatment Score ≥ 15.
Time Frame
24 month after operation
Title
Success Rate of Neurological Status
Description
Success rate of neurological status is reported as the percentage of participants who met neurological success defined as maintenance or improvement in all sections (motor, sensory, reflex, and straight leg raising) for the time period evaluated. In order for a section to be considered a success, each element in the section must remain the same or improve from the time of the preoperative evaluation to the time period evaluated.
Time Frame
24 month after operation
Title
Back Pain
Description
Numerical rating scales are used to evaluate back pain intensity and frequency. Patients will rate their pain intensity on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be." Similarly, patients will record their back pain frequency on a scale from 0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time." A patient's total pain score will be the sum of pain intensity and frequency scores (0 min, 20 max).
Time Frame
24 month after operation
Title
Back Pain Success Rate
Description
Back pain success rate is reported as the percentage of participants whose back pain improvement met: (Pre Score - Post Score)/ Pre Score > 20%.
Time Frame
24 month after operation
Title
Leg Pain
Description
Numerical rating scales are used to evaluate leg intensity and frequency. Patients will rate their pain intensity on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be." Similarly, patients will record their back pain frequency on a scale from 0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time." A patient's total pain score will be the sum of pain intensity and frequency scores (0 min, 20 max).
Time Frame
24 month after operation
Title
Leg Pain Success Rate
Description
Leg pain success rate is reported as the percentage of participants whose leg pain improvement met: (Pre Score - Post Score)/ Pre Score > 20%.
Time Frame
24 month after operation
Title
General Health Status (SF-36)
Description
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used to assess general health status. The SF-36 results are summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). The score for PCS and MCS is between 0 and 100, with higher scores denoting better quality of life.
Time Frame
24 month after operation
Title
Success Rate of SF-36 Health Survey
Description
Success rate of SF-36 Health Survey include two components: the success rate of a physical component summary (PCS) and the success rate of a mental component summary (MCS). The success rates of SF-36 PCS and MCS for DIAM Device vs. Single-Level Posterior Decompression were defined as: (Post Score - Pre Score) / Pre Score>= 20%. The success rates of SF-36 PCS and MCS for DIAM vs. Posterolateral Interbody Fusion were defined as: Post Score - Pre Score >= 0.
Time Frame
24 month after operation
Title
Operative Time
Time Frame
at the time of operation
Title
Blood Loss
Time Frame
At the time of operation
Title
Hospital Stay
Time Frame
At the time of discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has a symptom complex consisting of back, buttock, or groin pain (excluding symptomatic coxarthrosis) with leg pain typical of intermittent neurogenic claudication, which is defined as leg(usually calf) discomfort, pain, numbness, paresthesias, weakness, or fatigue aggravated by standing or walking and is only relieved with resting in flexed lumbar spine position Leg pain score ≥ 8 and back pain score ≥ 6 based on the Preop Back/ Leg Pain CRF. Leg pain score must be ≥ back pain score Narrowing of the lumbar spinal canal and/or intervertebral foramen at L2-L3, L3-L4, L4-L5 as indicated by MRI, with other MRI findings typical of spinal stenosis, such as trefoil canal shape; hypertrophy, thickening, buckling, or infolding of the ligamentum flavum; hypertrophied facet joints or facet joint capsule; annular bulging; or lateral (subarticular) stenosis. Must sit for at least 30 min without severe pain Must walk at least 100 ft unassisted 35 yrs of age, inclusive Preoperative Oswestry score ≥ 40 Child-bearing potential, pt is not pregnant or nursing and agrees not to become pregnant during study period Treated non-operatively for a pd of at least 6 mos Willing and able to comply with study plan and able to understand and sign Pt ICF Exclusion Criteria: Disease state which requires destabilizing decompression Axial back pain with no pain in leg, buttock, or groin Baseline strength grade of 0 (total paralysis), 1 (palpable or visible contraction), or 2 (active movement, gravity,eliminated) in any lower extremity motor group as noted on Neuro Status CRF Segmental kyphosis >0° at indicated level Cauda equina syndrome Compression of nerve roots that causes neurogenic bowel, bladder dysfunction Prior surgical procedure at involved or adjacent levels Diagnosed with significant peripheral neuropathy Significant vascular disease causing vascular claudication Requires tx of spinal stenosis at more than 1 lumbar level Significant lumbar instability, defined as > 3mm translation on flexion/extension radiographs Has > 3mm fixed spondylolisthesis at affected level BMI ≥ 40 Sustained vertebral or hip fracture within last year Has the following (if "Yes" to any risk below, a lumbar spine DEXA Scan is required for eligibility) Previous diagnosis of osteoporosis, osteopenia, or osteomalacia Postmenopausal Non-Black female over age of 60 who weighs ≤ 140 lbs Postmenopausal female who has sustained a non traumatic hip, spine or wrist fracture Male over age of 60 who has sustained non-traumatic hip or spine fracture If level of DEXA T-score is -1.0 or lower pt is excluded from study Lumbar scoliosis with Cobb angle of > 15° Documented allergy to silicone, polyethylene, titanium or latex Overt or active bacterial infection, local, systemic, and/or potential for bacteremia Alcohol and/or drug abuser Received tx with investigational therapy (device and/or pharmaceutical) within 30 days prior to entering study or such tx is planned during the 24 mos following enrollment in study Suppressed immune system or has taken steroids at any dose daily for more than 1 mon within the last yr Presence of active malignancy or prior history of malignancy except for basal cell carcinoma of the skin History of any endocrine or metabolic disorder known to affect osteogenesis Chronic or acute renal and/or hepatic failure or prior history of renal and/or hepatic parenchymal disease History of autoimmune disease Disease which precludes accurate clinical evaluation of safety and effectiveness of txs in this study Congenital or iatrogenic posterior element insufficiency Moderate to advance spondylosis or pts who demonstrate advanced degenerative changes. Such advanced degenerative changes are characterized by 1 or combination of the following a Bridging osteophytes; b Reduction or absence of motion; c Collapse of the intervertebral disc space of > 50% of its normal ht Mentally incompetent Waddell Signs of Inorganic Behavior score of ≥ 3 Prisoner
Facility Information:
City
Fremont
State/Province
California
Country
United States
City
Jacksonville
State/Province
Florida
Country
United States
City
Melbourne
State/Province
Florida
Country
United States
City
Temple Terrace
State/Province
Florida
Country
United States
City
Columbus
State/Province
Georgia
Country
United States
City
Baton Rouge
State/Province
Louisiana
Country
United States
City
New Orleans
State/Province
Louisiana
Country
United States
City
Winston-Salem
State/Province
North Carolina
Country
United States
City
Chattanooga
State/Province
Tennessee
Country
United States

12. IPD Sharing Statement

Learn more about this trial

DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral Fusion

We'll reach out to this number within 24 hrs